Asia Tech Wire (July 2) -- U.S. private equity firm Blackstone is to sell Japanese drugmaker Alinamin Pharmaceutical to Asian investment fund MBK Partners for 350 billion yen ($2.17 billion), according to Nikkei.

Alinamin was formerly the Japanese consumer healthcare division of Takeda Pharmaceutical (TOKYO:4502, NYSE:TAK).

The division's flagship products include Alinamin, Japan's first vitamin B1 derivative, and a cold remedy called Benza.

In April 2021, Takeda announced the completion of the sale of the business to Blackstone for a total transaction value of 242 billion yen.